CLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV)



Similar documents
Preetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, International Journal of Phytopharmacology

GP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014

Nail psoriasis in Germany: epidemiology and burden of disease M. Augustin, K. Reich,* C. Blome, I. Schäfer, A. Laass and M.A.

Frequency and pattern of nail changes in patients with psoriasis vulgaris

Nail disorders. Prof. MUDr. Petr Arenberger, DrSc, MBA

L. Williamson, N. Dalbeth, J. L. Dockerty, B. C. Gee 1, R. Weatherall 2 and B. P. Wordsworth

Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment

Psoriasis Treatment Transition Pathway

Approach to managing patients with nail psoriasis

Psoriasis Can be Cured with Homoeopathy

Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States

Psoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?

PSORIASIS THE RELATIONSHIP BETWEEN NAIL CHANGES, THE EVOLUTION AND THE CLINICAL FORM OF THE DISEASE

Phenotypes and Classification of Psoriasis

Instrument: Nail Assessment in Psoriasis and Psoriatic Arthritis

TNF-α Antagonists in the Treatment of Nail Psoriasis

Review Article. Review of nail psoriasis. Introduction. Impact of nail psoriasis. CT Chau

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Key words: Clinical features, early onset, late onset, psoriasis

X-Plain Psoriasis Reference Summary

Psoriasis; a new marker for Hepatitis C among Egyptian Patients

Nail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis

Adalimumab for the treatment of psoriasis

More details >>> HERE <<<

How To Treat Psoriasis With Omega 3 Fatty Acids

Additional details >>> HERE <<<

Patient reported symptoms of psoriasis: results from the Psoriasis SELECT Patient Study

Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis

For more information, please contact the National Psoriasis Foundation at or

Highlights on Clinical Picture of Psoriasis

Interventions for nail psoriasis (Review)

Psoriasis. Student's Name. Institution. Date of Submission

PATIENT RESOURCES: PSORIASIS

Your psoriasis story. Print this out, answer the questions, then share it with your doctor

Measurement of epidermal thickness in a patient with psoriasis by computer-supported image analysis

PSORIASIS. -Multi factorial. -Papulosquamous disorder. -Genetically determined (few) -Chronic Scaly lesions. -Seasonal variations

1. Title 2. Background

More information >>> HERE <<<

Nail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis

teaching hospital and research centre, Himayath sagar road, Hyderabad, Telangana state, India 2

Azathioprine pulse therapy in the treatment of psoriasis

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac

Original Article ABSTRACT

Before I go into detailed development process, let me draw the attention to this fact that

Summary of the risk management plan (RMP) for Otezla (apremilast)

Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS

Methods of Outcomes Measurement in Nail Psoriasis

Subclinical Enthesitis: New Approach in the Clinical. Examination of Psoriatic Arthritis and Nails

Guideline for the use of Biological Therapies in the Treatment of Psoriasis

Development and Validation of a Screening Questionnaire for Psoriatic Arthritis

Draft Guidance on Calcipotriene

Etanercept in childhood psoriasis: An experience from Kuwait

Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features

Science > MultiClear. How the MultiClear works?

Childhood Psoriasis a challenge to all

Scottish Medicines Consortium

påçííáëü=jéçáåáåéë=`çåëçêíáìã==

Psoriasis - suspected

Laser Therapy for Plaque Psoriasis

Hitchcock Clinic Manchester, NH. Psoriasis. Overview. Psoriasis 3/9/2009. From heartbreak to heart attack. Mark Quitadamo, MD

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Systematic Review of UV-Based Therapy for Psoriasis

HLA-Cw*0602 associates with a twofold higher prevalence. of positive streptococcal throat swab at the onset of

GENETIC ANALYSIS OF PSORIASIS AND PSORIATIC ARTHRITIS Department of Dermatology, University of Michigan

Treating psoriasis and psoriatic arthritis. A booklet for patients and carers

Collaborative Association Study of Psoriasis. Gonçalo Abecasis, Anne Bowcock, James Elder, Jerry Krueger

A Psoriasis. Clinical Presentation. 2 Types of Psoriasis. Plaque Psoriasis. 1 Introduction

Psoriasis. Etiology. Clinical feature. Head to Toe Psoriasis, How to Treat? Precipitating factor 11/19/2012

Validation of an original questionnaire for patients with psoriatic arthritis: The Psoriatic Arthritis Impact Profile (PAIP)

An Assessment of the Cost-Utility of Therapy for Psoriasis

FastTest. You ve read the book now test yourself

Public Forum on Psoriasis National Series

Analysis of Factors Influencing Clinical Types of Psoriasis Vulgaris

Psoriasis Agents, Topical Review 01/18/2010

Additional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

Course: Acupuncture Treatment of Disease 3 Date: June 22, 2009 Class #: 10 Psoriasis, Fibromyalgia/CFS. Psoriasis

A patient guide to psoriasis/ psoriatic arthritis URAC. All Walgreens specialty pharmacy locations are ACHC and URAC accredited.

PSORIATIC ARTHRITIS. Chryssanthie Kafkala, M.D. INTRODUCTION:

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists

Nail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis

2-5 % Europeans A distressing, life-long, inflammatory disease Impairs patients Quality of Life

CLINICAL BRIEFS. Unmet Needs in the Management of Plaque Psoriasis

I. Background. II. Eligibility Geographic Scope: United States Only International(specify country/countries)

Role of oral colchicine in plaque type psoriasis. A randomized clinical trial comparing with oral methotrexate

Additional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?

TOPICAL TREATMENTS FOR PSORIASIS

CAN-FITE BIOPHARMA LTD.

M05.9 Rheumatoid arthritis with rheumatoid factor, unspecified M06.00 Rheumatoid arthritis without rheumatoid factor, unspecified site M06.

Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study

CLINICAL PRESENTATION OF PSORIASIS

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

Association between streptococcal throat infection and psoriasis in Bangladesh

BJD. Summary. British Journal of Dermatology THERAPEUTICS

Dr. Hanne Melchior. Prof. Dr. Holger Schulz Dr. Jochen Walker Prof. Dr. Dr. Martin Härter. WIC Policy Conference Berlin June 5th 2015

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd

Efficacy and safety of simvastatin in chronic plaque psoriasis

Transcription:

Southeast-Asian J. of Sciences: Vol. 2, No 1 (2013) pp. 101-107 CLINICAL MANIFESTATIONS OF PSORIATIC NAIL AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY (NHDV) Nguyen Huu Sau and Nguyen Minh Thu Hanoi medical university Hanoi, Vietnam e-mail: nguyenhuusau@yahoo.com The National hospital of dermatology and venereology Hanoi- Vietnam Abstract Psoriasis is a common skin disease and nails are frequently involved. Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective: investigating clinical manifestations of psoriatic nail at the National hospital of dermatology and venereology (NHDV). Material and method: the descriptive study was performed basing on data of all patients with psoriasis from 03/2012 to 04/2012. Results: There were 95 patients having nail lesion, accounting for 63,3% of psoriasis patients visit at NHDV, with mean nail psoriasis severity index (NAPSI) score was 43,26 ± 31,45. The proportion of psoriatic nail among difference types of psoriasis: 72,2% of plaque psoriasis, 81,2% of erythrodermic psoriasis, 34,3% of guttate psoriasis and 45,5% of pustular psoriasis. The yellow-brown and crumbling nail was the most common lesion. The mean PASI score was 18,51 8,27 and 8,25 ± 4,64 in patients with and without nail involvement, respectively. The linear relationship between NAPSI and PASI could be represented by the following equation: PASI = 0,17 NAPSI + 8,83, coefficient of determination r = 0,85. Key words: psoriasis, psoriatic nail, NAPSI. 101

102 Clinical manifestations of psoriatic nail at the national hospital of... I. INTRODUCTION Nail involvement is very common in the course of psoriasis. Nail psoriasis is reported to affect 80% of patients with psoriasis at some point in their lives. It has been shown to be associated with longer duration of skin lesions. In addition, there is a positive association between the duration of psoriasis and the severity of nail involvement. A number of studies which focused on the relationship between the psoriasis area and severity index (PASI) and NAPSI have been published. However there have been limited such studies in Viet Nam. The main purpose of this research was to assess nail lesion in psoriasis patient in NHDV. II. MATERIAL AND METHOD 2.1. Material and method Material: - patients diagnosed as psoriasis who were examined and treated at NHDV from 03/2012 to 04/2012. Method: - A descriptive study was performed - Procedure: + Ask patients about: clinical history, duration of disease, time of nail lesion. + Clinical examination, photography, evaluates PASI and NAPSI score. 2.2. Statistical analysis: SPSS 16.0 III. RESULT 3.1. Prevalence of nail involvement Of 150 patients examined and treated at NHDV in March and April 2012, nail lesions were seen in 95 patients, accounting for 63,3%.

N. H. Sau and N. M. Thu 103 3.2 Prevalence of nail involvement of psoriasiss types Number of patients with each type of psoriasis: 72 patients with plaque psoriasis, 32 patients with erythrodermic psoriasis, 35 patients with guttate psoriasis and 16 patients with pustular psoriasis. The erythrodermic patients had highest nail lesion prevalence (81,2%), followed by plaque patients (72,2%), pustular psoriasis (45,5%), and the guttate patients had the lowest prevalence (34,3%) 3.3. Prevalence of clinical forms of nail psoriasis The most common nail lesions was nail discoloration, which was present in approximately 80%, this was followed by districted nail (58,9%) and pitting

104 Clinical manifestations of psoriatic nail at the national hospital of... (42,1%). The least common form are oil drop sign (accounting for 26,3%) and subungual hyperkeratosis (33,7%). 3.4. The mean PASI score The mean PASI score was 18,51 ± 8,27 and 8,25 ± 4,64 in patients with and without nail involvement, respectively. 3.5. Disease duration Maximum number of patients i.e. 17 (40,3%) were affected by the disease from 5-10 years while in only 6 (12,6%) patients, disease duration was < 1 years.

N. H. Sau and N. M. Thu 105 3.6. Association between NAPSI and PASI There is a linear relationship between PASI and NAPSI: PASI = 0,17 NAPSI + 8.83 with r = 0,85. IV. DISCUSSION Among 150 patients examined and treated at NHDV in March and April 2012, the number of patients with nail lesions were 95, significantly higher than the group without nail involvement (p < 0,05). According to Phoebe Rich and Christopher E.M.Griffiths, nail psoriasis reportedly affects 10% to 50% of patients with psoriatic skin lesions and is positively associated with both longer duration and greater extent of skin disease. It is estimated that nearly 90% psoriasis patients have nail lesions at some point in their lives [6]. Salomon J. suggested that 78% of inpatient has nail lesions [7]. The mean NAPSI score in our research was measured as 43,26 ± 31,45, higher than Hallaji Z. (15,15 ± 26,37) and C. Fischer Levancini (14,3 ± 6,34) [3],[2]. The primary reason for these differences are subjects and disease duration. Our subjects are mainly in-patient with more severe skin and nail involvement. In addition, limitation in living standard and awareness has prevented our patients from accessing health care service earlier. Among psoriasis patients in our research, the most common type is plaque psoriasis (account for 48%), followed by guttate psoriasis (23,3%). Pustular and erythrodermic psoriasis, which mainly caused by inappropriate treatment with unknown original herbs, are severe type with lower prevalence (7,3% and 21,3% respectively). 72 patients with plaque psoriasis, 32 patients with ery-

106 Clinical manifestations of psoriatic nail at the national hospital of... throdermic psoriasis, 35 patients with guttate psoriasis and 16 patients with pustular psoriasis. The highest nail lesion prevalence was observed in erythrodermic and plaque patients (with 81,2% and 72,2% respectively). In pustular and guttate patients the prevalence was lower (45,5% and 34,3% respectively). The correlation between nail involvement and severe skin lesion, which was concerned in many other researches, could be responsible for differences in prevalence of nail psoriasis. In addition, limitation in number of subjects, the small sample size resulted in reality prevalence. The most common nail involvement in psoriasis patients was nail discoloration, which was present in approximately 80%, this was followed by districted nail (58,9%) and pitting (42,1%). The least common form are oil drop sign (accounting for 26,3%) and subungual hyperkeratosis (33,7%). It was recognized that patients who had short disease duration and mild skin lesion, the nail involvement was usually absent or pitting nail. The number of nails pitting is positively associated with disease duration. The most common nail involvement in patients with long disease duration, severe skin disease are districted nail subungual hyperkeratosis, and discoloration. The average disease duration is 4,34 ± 10,21 year. 40,3% and 10,3% of patients were affected by the disease from 5 to 10 year and over 10 year, respectively. Thus, long disease duration of psoriasis patients in our research has substantial influence on distribution of nail involvement. It is necessary to have more research with bigger sample size and longer time to access the reality of nail involvement. The nail psoriasis severity index has recently been reported as a possible reproducible, objective, and simple tool for clinical assessment of psoriatic nail disease. In our research, PASI and NAPSI were used to access the severity of nail and skin s involvement as well as correlation between nail involvement and skin disorder [5]. Because PASI score should only be used for expressing disease severity of plaque psoriasis, pustular and guttate psoriatic patient were not evaluated. According to figure 4, patients with nail involvement have a statistically significantly higher mean score than the other group (18,51 ± 8,27 in comparison with 8,25 ± 4,64). There was a closely correlation between PASI and NAPSI score. By the linear regression analysis of scores, the following equation seems to best represent the relationship: PASI = 0,17 NAPSI + 8.83 and r = 0,85. The relationship between the severity of skin and nail disease is a matter of controversy. Rich et al reported no correlation between baseline NAPSI and PASI scores [6]. On the other hand, Zahra Hallaji et al (2010) suggested a significant weak association between the severity of nail disease and skin disorder with equation PASI = 0.11 NAPSI + 6.36 and r = 0,1 [3]. In addition, Williamson et al (2004) suggested a significant association between the severity of nail disease as measured by the Psoriasis Nail Severity Score (PNSS) and the severity of psoriasis measured by the percentage of body surface area and the physicians global assessment of the disease. In conclusion, nail psoriasis occurs frequently in patients with psoriatic skin

N. H. Sau and N. M. Thu 107 lesions, especially with long disease duration. It has been reported that nail disorder significantly associated with severe skin involvement. Although there are effective treatment approaches for skin lesions, treatment of nail psoriasis is rather difficult. V. CONCLUSION There were 150 patients who patients diagnosed as psoriasis, examined and treated at NHDV from 03/2012 to 04/2012: - 95 patients has nail lesion, accounting for 63,3% - The highest proportion of psoriatic nail among difference types of psoriasis: 72,2% of plaque psoriasis, 81,2% of erythrodermic psoriasis, - The discoloration (78,9%) and districted nail (58,9%) were the most common lesion. - The mean PASI score was 18,51 ± 8,27 and 8,25 ± 4,64 in patients with and without nail involvement, respectively. - The linear relationship between NAPSI and PASI could be represented by the following equation: PASI = 0,17 NAPSI + 8,83, coefficient of determination r = 0,85. References [1] S. E. Cassell, J. D. Bieber, P. Rich et al., The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis, J Rheumatol, 34(2007).123-129. [2] C. Fischer-Levancini, M. Snchez-Regaa, F. Llambí et al., Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment, Actas Dermosifiliogr, 103(8)(2012), 725-728. [3] Z. Hallaji, F. Babaeijandaghi, M. Akbarzadeh et al., A significant association exists between the severity of nail and skin involvement in psoriasis, J. Am. Acad Dermatol, 66(1)(2012), e1 2-3. [4] M. M. Jiaravuthisan,D. Sasseville, R. B. Vender, et al., Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy, J. Am. Acad Dermatol, 57(2007), 1-27. [5] P. Rich and R. Scher, Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis, J. Am. Acad Dermatol, 49(2003), 206-12. [6] P. Rich, C. Griffiths, K. Reich et al., Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year, J. Am. Acad. Dermatol, 58(2008), 224-31. [7] J. Salomon, J. C. Szepietowski and A. Proniewicz, Psoriatic nails: a prospective clinical study, J. Cutan Med. Surg., 7(2003), 317-21. [8] L. Williamson, N. Dalbeth, J. Dockerty et al., Extended report: nail disease in psoriatic arthritiseclinically important, potentially treatable and often overlooked, Rheumatology, 43(2004), 790.